{"disease":{"id":"respiratory-syncytial-virus-infection","name":"Respiratory Syncytial Virus Infection","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":1,"trial_count":4},"drugs":{"marketed":[{"drug_id":"ribavarin","indication_name":"Respiratory syncytial virus infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ribavarin","company_name":"Charles University, Czech Republic","drug_phase":"discontinued","molecular_target":"Cytosolic purine 5'-nucleotidase, Adenosine kinase, Ectonucleotide pyrophosphatase/phosphodiesterase family member 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"active","indication_name":"Respiratory Syncytial Virus Infections","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Active","generic_name":"active","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"Sisunatovir","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"rv521","indication_name":"Respiratory Syncytial Virus Infections","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"RV521","generic_name":"rv521","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"RV521 drug in capsules","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"sisunatovir","indication_name":"Respiratory Syncytial Virus Infection","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sisunatovir","generic_name":"sisunatovir","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"Participants will receive tablets from Day 1 to Day 5","quality_score":10,"revenue":null,"mechanism":""}],"offLabel":[],"totalMarketed":1,"totalPipeline":3},"trials":{"data":[{"nct_id":"NCT01155193","title":"Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany","phase":"","overall_status":"COMPLETED","enrollment_count":30804,"lead_sponsor_name":"AbbVie (prior sponsor, Abbott)","has_results":true},{"nct_id":"NCT04886596","title":"Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":26675,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT05238025","title":"MVA-BN-RSV Vaccine Trial","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":20419,"lead_sponsor_name":"Bavarian Nordic","has_results":true},{"nct_id":"NCT04605159","title":"A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":11194,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT06534892","title":"An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10212,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT04623047","title":"Infection Watch Study","phase":"","overall_status":"COMPLETED","enrollment_count":10034,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT03627572","title":"RESCEU Study: Defining the Burden of Disease of Respiratory Syncytial Virus in Europe in Infants","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT07358910","title":"Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Institut Pasteur du Cambodge","has_results":false},{"nct_id":"NCT06185647","title":"Evaluation in Practice of the Impact of NIrsevimab on EmeRgency Use for BRONCHIOlitis","phase":"","overall_status":"COMPLETED","enrollment_count":4924,"lead_sponsor_name":"Hôpital Armand Trousseau","has_results":false},{"nct_id":"NCT06251024","title":"Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and Older","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":4541,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT03614676","title":"A Study of Outcomes and Events of Interest in Pregnant Women, Neonates and Infants and of RSV Surveillance","phase":"NA","overall_status":"COMPLETED","enrollment_count":4493,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT07346963","title":"RSV-Positive Children <5 Years Presenting to Pediatric Emergency Departments in Türkiye: TRUST-RSV","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":4000,"lead_sponsor_name":"Eskisehir Osmangazi University","has_results":false},{"nct_id":"NCT05705440","title":"A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3855,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT04767373","title":"Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":3632,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05913700","title":"Effect of Respiratory Virus Infection on EmeRgencY Admission Study (EVERY Study)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3067,"lead_sponsor_name":"Institute for Clinical Effectiveness, Japan","has_results":false},{"nct_id":"NCT03979313","title":"A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3012,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT07164430","title":"The Impact of the 2025 Infant and Maternal Respiratory Syncytial Virus (RSV) Prevention Program on RSV-related Hospitalisations in the Australian Capital Territory","phase":"","overall_status":"COMPLETED","enrollment_count":2792,"lead_sponsor_name":"Nicola Irwin","has_results":false},{"nct_id":"NCT06551181","title":"A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2621,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT06083623","title":"A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":2282,"lead_sponsor_name":"Zhuhai Trinomab Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04288921","title":"Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing Sites","phase":"NA","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"LumiraDx UK Limited","has_results":false},{"nct_id":"NCT03698084","title":"RESCEU: Defining the Burden of RSV Disease","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT04732871","title":"Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1720,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT05045144","title":"A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1586,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT05590403","title":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1544,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT06389487","title":"A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1459,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02878330","title":"A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1453,"lead_sponsor_name":"MedImmune LLC","has_results":true},{"nct_id":"NCT05562817","title":"The Epidemiology , Health and Economic Burden of RSV Amongst Hospitalized Children Under 5 Years of Age in Jordan","phase":"","overall_status":"UNKNOWN","enrollment_count":1200,"lead_sponsor_name":"MENA Center for Research & Development and Internship","has_results":false},{"nct_id":"NCT02325791","title":"Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1177,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT05070546","title":"A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1124,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT05879107","title":"Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1113,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT06546800","title":"SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1100,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT07279298","title":"Effectiveness of Immunization in Preventing Severe Acute Respiratory Infection RSV","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1097,"lead_sponsor_name":"Bogotá District Health Secretariat","has_results":false},{"nct_id":"NCT03814590","title":"A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":1053,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT05568797","title":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1045,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03621930","title":"RESCEU Study, Defining the Burden of Disease of RSV in Older Adults","phase":"","overall_status":"UNKNOWN","enrollment_count":1040,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT05559476","title":"A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1029,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT07239583","title":"Genotype and Disease Burden of RSV in Older Vietnamese Adults (RSV: Respiratory Syncytial Virus )","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Tam Anh Research Institute","has_results":false},{"nct_id":"NCT06392451","title":"LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"DiaSorin Molecular LLC","has_results":false},{"nct_id":"NCT04841577","title":"A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":976,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03959488","title":"A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":925,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT06374394","title":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":841,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT05059301","title":"A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":770,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT06614725","title":"A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":751,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT07220109","title":"A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT06134648","title":"Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":646,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT06237296","title":"Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":558,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":false},{"nct_id":"NCT04126213","title":"Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":534,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT05966090","title":"A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":530,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT04138056","title":"A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":509,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02360475","title":"Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":507,"lead_sponsor_name":"GlaxoSmithKline","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}